title: Commentary: the PROactive study--the glass is half full.
authors.affiliation: Tulane University Medical Center, New Orleans, Louisiana 70112, USA. vfonseca@tulane.edu
authors.forename: Vivian
authors.initials: V
authors.lastname: Fonseca
authors.forename: Ali
authors.initials: A
authors.lastname: Jawa
authors.forename: Sunil
authors.initials: S
authors.lastname: Asnani
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D007333:Insulin Resistance; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control; D000077205:Pioglitazone; D020521:Stroke / Q000401:mortality / Q000517:prevention & control; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone